
20n YCアプリケーション
20nはWinter 2015バッチでHealthcare企業としてY Combinatorを卒業しました。以下:会社の事業内容、創業者、そして実際のYCフォームで質問ごとに再構築されたYCへの応募内容。
- YCバッチ
- Winter 2015
- 業界
- HealthcareIndustrial Bio
- チーム規模
- 2
- ステータス
- Inactive
- ローンチ済み
- 2014
創業者
Saurabh SrivastavaFounder/CEO
Chris AndersonFounder/CSO
20nの事業内容
The next decade is going to see a biotech revolution fueled by three technologies: ability to read DNA (sequencing), ability to write DNA (synthesis), and computational systems that predict what DNA to read and write. With sequencing and synthesis being mainstream now [1], 20n provides the computational systems that predict DNA design for novel industrial biotech and health applications. At 20n, we are taking a fresh look at turning biological data into information. We approach it as a big data learning problem, and bring to bear techniques from machine learning, distributed systems, AI planning, program synthesis, data mining, and natural language processing. With the support of DARPA [2], we are building a team of computer scientists, and bioengineers to look at biology in fundamentally new ways. Our current customers include industrial biotech firms that are leading the charge in transitioning us from traditional unsustainable means of manufacturing to sustainable biological processes leading to advanced fuels, materials, therapeutics, and flavors and fragrances. 20n’s technology helps them enter markets previously thought inaccessible for biology. [1] Sequencing DNA costs $4k/genome ( and is expected to go down to $1k/genome. Synthesizing DNA is at 20cents/bp, and is expected to go down to 0.1cents/bp. [2] DARPA in the past supported work that led to the internet, stealth planes, GPS, and even Douglas Engelbart’s mother-of-all-demos.
20nのYCアプリケーション、再構築済み
Y Combinator 申請
20n 様、Winter 2015 バッチ。公開データから回答された、実際のフォームの質問。
- Founders2
- Company7
- Progress7
- Idea4
- Equity3
- Curious2
- Batch Preference1
Company
20n
Using AI to predict biochemistry for manufacturing
We are building computational systems that use AI and machine learning to predict DNA designs for industrial biotech and therapeutics. Our product helps industrial biotech firms design biological systems that can produce fuels, materials, flavors, and medicines that were previously inaccessible by traditional methods.
We live in San Francisco, CA, and would base the company here after YC.
San Francisco has the technical talent and biotech ecosystem we need to grow. It keeps us close to early industrial biotech customers and partners.
よくある質問
20nの実際のYCアプリケーションですか?
いいえ。Y Combinatorは提出されたアプリケーションを非公開にしています。これは再構築されたものです。実際のYCフォームの質問に、20nの公開データ(ローンチノート、創業者経歴、製品説明)から回答しています。20nのような会社がYCにどのようにアピールするかを示しており、彼らが提出したテキストではありません。
20nはどのYCバッチに参加しましたか?
20nはY CombinatorのWinter 2015バッチに参加しました。
20nは誰によって設立されましたか?
20nはSaurabh Srivastava, Chris Andersonによって設立されました。
20nは何をしていますか?
Using AI to predict biochemistry for manufacturing and therapeutics
完全な再構築されたアプリケーションはどのように読めばよいですか?
無料のRound Fundedアカウントを作成してください。 20nの26つの回答からなる完全なアプリケーションと、他のすべてのYCバッチはYC Insightsにあります。